Galectin Therapeutics (PHPN) Ratios
Galectin Therapeutics Ratios
DE:PHPN's free cash flow for Q2 2026 was $-2.44M. For the 2026 fiscal year, DE:PHPN's free cash flow was increased by $0.00 and operating cash flow was $-2.44M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 |
| Quick Ratio | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 |
| Cash Ratio | 2.21 | 0.43 | 1.64 | 1.43 | 4.39 |
| Solvency Ratio | -0.21 | -0.39 | -0.46 | -0.72 | -0.78 |
| Operating Cash Flow Ratio | -2.97 | -1.18 | -2.10 | -2.39 | -2.69 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -1.98 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -126.29M | $ -103.31M | $ -60.73M | $ -32.93M | $ 2.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 6.85 | 6.07 | 2.55 | 1.87 | 0.69 |
| Debt-to-Equity Ratio | -1.06 | -1.03 | -1.19 | -1.24 | 11.11 |
| Debt-to-Capital Ratio | 17.69 | 33.46 | 6.21 | 5.20 | 0.92 |
| Long-Term Debt-to-Capital Ratio | 17.74 | -4.74 | 6.24 | 5.22 | 0.92 |
| Financial Leverage Ratio | -0.15 | -0.17 | -0.47 | -0.66 | 15.99 |
| Debt Service Coverage Ratio | -3.20 | -1.56 | -13.70 | -36.51 | -61.34 |
| Interest Coverage Ratio | -2.74 | -7.66 | -13.64 | -37.13 | -61.72 |
| Debt to Market Cap | 0.50 | 1.32 | 0.72 | 0.59 | 0.24 |
| Interest Debt Per Share | 2.21 | 1.79 | 1.24 | 0.69 | 0.50 |
| Net Debt to EBITDA | -4.95 | -2.20 | -1.21 | -0.56 | 0.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 153.53% | 110.87% | 107.86% | 101.11% | 101.15% |
| Return on Assets (ROA) | -157.87% | -268.92% | -145.62% | -182.18% | -72.98% |
| Return on Equity (ROE) | 24.44% | 45.65% | 68.17% | 120.44% | -1166.93% |
| Return on Capital Employed (ROCE) | -174.62% | 236.87% | -303.99% | -463.58% | -92.03% |
| Return on Invested Capital (ROIC) | -174.29% | -1316.98% | -302.88% | -461.35% | -92.00% |
| Return on Tangible Assets | -157.87% | -268.92% | -145.62% | -182.18% | -72.98% |
| Earnings Yield | -11.60% | -58.53% | -41.12% | -57.78% | -25.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -71130.76 | -44370.31 | -16068.90 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 71130.76 | 44370.31 | 16068.90 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.37 | -0.67 | -0.55 | -0.52 | -0.42 |
| Free Cash Flow Per Share | -0.37 | -0.67 | -0.55 | -0.52 | -0.42 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -458.98 | 0.00 | 0.00 | -142.15 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.18 | -0.39 | -0.46 | -0.78 | -0.84 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -8.98% | -51.96% | -33.01% | -46.28% | -20.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.67 | -1.70 | -2.43 | -1.73 | -3.97 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -2.11 | -0.78 | -1.66 | -2.08 | 46.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.13 | -1.92 | -3.03 | -2.16 | -4.98 |
| Price-to-Operating Cash Flow Ratio | -11.13 | -1.92 | -3.03 | -2.16 | -4.98 |
| Price-to-Earnings Growth (PEG) Ratio | 0.24 | -0.63 | -0.18 | -0.07 | -0.15 |
| Enterprise Value Multiple | -16.28 | -4.14 | -3.82 | -2.34 | -3.69 |
| Enterprise Value | 381.87M | 171.50M | 146.01M | 88.39M | 110.56M |
| EV to EBITDA | -16.28 | -4.14 | -3.82 | -2.34 | -3.69 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -15.99 | -4.11 | -4.43 | -2.85 | -4.55 |
| EV to Operating Cash Flow | -15.99 | -4.11 | -4.43 | -2.85 | -4.55 |
| Tangible Book Value Per Share | -1.97 | -1.65 | -1.00 | -0.54 | 0.04 |
| Shareholders’ Equity Per Share | -1.97 | -1.65 | -1.00 | -0.54 | 0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.48 | -0.76 | -0.68 | -0.65 | -0.52 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.31 | 1.13 | 1.07 | 1.03 | 1.02 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.77 | 0.89 | 0.80 | 0.80 | 0.80 |
Currency in USD
